References
- Podolsky DK. Inflammatory bowel disease. New Engl J Med. 2002;347:417–429.
- Pineton de Chambrun G, Peyrin-Biroulet L, Jf C, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastro Hepat. 2010;7:15–29.
- Iacucci M, De Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010;24:127–133.
- Laroui H, Theiss AL, Sitaraman SV, et al. Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials. 2011;32:1218–1228.
- Kriegel C, Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release. 2011;150:77–86.
- Grimpen F, Pavli P. Advances in the management of inflammatory bowel disease. Intern Med J. 2010;40:258–264.
- Laroui H, Dalmasso G, Merlin D, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(843–53):e1–e2.
- Lautenschlager C, Schmidt C, Stallmach A, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2011;71:58–76.
- Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–151.
- Awasthi VD, Goins B, Phillips WT, et al. Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J Drug Target. 2002;10:419–427.
- Watanabe A, Tanaka H, Ohkawara T, et al. Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model. Int J Pharm. 2016;509:118–122.
- Lee Y, Kim H, Jon S, et al. Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy. Angew Chem. 2016;55:7460–7463.
- Peer D, Park EJ, Shimaoka M, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319:627–630.
- Maisel K, Ensign L, Hanes J, et al. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2015;197:48–57.
- Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235–246.
- Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv. 2012;9:1393–1407.
- Laroui H, Wilson DS, Sitaraman SV, et al. Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol. 2011;300:G371–83.
- ScottWilson D. Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9(11):923–928.
- Xiao B, Laroui H, Zhang Y, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials. 2013;34:7471–7482.
- Zhang J, Tang C, Yin CH. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013;34:3667–3677.
- Laroui H, Viennois E, Xiao B, et al. Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonicmacrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41.
- Charania MA, Laroui H, Xiao B, et al. Intestinal epithelial CD98 directly modulates the innate host response to enteric bacterial pathogens. Infect Immun. 2013;81:923–934.
- MacKinnon AC, Farnworth SL, Leffler H, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180:2650–2658.
- Xiao B, Yang Y, Baker M, et al. Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle. J Mater Chem B. 2014;2:1499–1508.
- Farkas S, Hornung M, Herfarth H, et al. Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Expe Immunol. 2005;142:260–267.
- Vafaei SY, Esmaeili M, Dinarvand R, et al. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohyd Polym. 2016;144:371–381.
- Xiao B, Xu Z, Zhang M, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017. DOI:10.1016/j.ymthe.2016.11.020.